Lupin Ltd — Capital/Financing Update 2020

Aug 6, 2020

August 6, 2020

==> picture [84 x 99] intentionally omitted <==

 BSE Limited,

Department of Corporate Services, P. J. Towers, Dalal Street, Mumbai Samachar Marg, MUMBAI - 400 001.

National Stock Exchange of India Ltd.,

Exchange Plaza, Bandra Kurla Complex, Bandra (East), MUMBAI - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Enclosed is a Revised Press Release as regards agreement entered into with ForDoz Pharma Corp for granting the Company, exclusive rights to market and distribute two complex injectable assets in advanced stages of development in the U.S. and its territories.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For LUPIN LIMITED

RAJVARD Digitally signed by RAJVARDHAN VISHNU SATAM DN: c=IN, o=Personal, postalCode=400062, HAN st=Maharashtra, 2.5.4.20=c19d8ef961d9fa59e973a0 93a4d3924b2532eb2f496ea7e2abc f74700f5375b7, VISHNU serialNumber=df8ebe60a88c796663c738ea25bfa0b475d195f726cdb6 7a2ff09c4242771b2a, SATAM cn=RAJVARDHAN VISHNU SATAM Date: 2020.08.06 17:25:06 +05'30'

R. V. SATAM COMPANY SECRETARY (ACS - 11973)

Encl- : a/a.

Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com

www.lupin.com

Press Release

==> picture [67 x 70] intentionally omitted <==

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN

Lupin Signs Exclusive Distribution Pact with ForDoz Pharma for 2 Complex Injectable Assets Under Development

Mumbai, Baltimore, August 06, 2020: Pharma major Lupin Limited (Lupin) announced today that its U.S. based wholly-owned subsidiary Lupin Inc. has entered into an agreement with ForDoz Pharma Corp (ForDoz) for granting Lupin the exclusive rights to market and distribute 2 complex injectable assets in advanced stages of development in the U.S. and its territories.

The two assets are in the Oncology and Anti-infective therapeutic areas which when approved, will provide affordable alternatives to patients and healthcare professionals.

The assets will be manufactured in ForDoz’s U.S. based manufacturing site and ForDoz will be responsible for the development, and obtaining the necessary regulatory approvals. Lupin shall leverage its existing commercial infrastructure for marketing and distribution of the two assets.

Commenting on the development Alok Sonig, CEO, US Generics and Global Head, Generics R&D and Biosimilars for Lupin said, “The partnered assets are a key, strategic addition to our complex injectables pipeline and will bolster our Institutional business offering. These assets will complement Lupin’s ongoing organic R&D efforts in complex assets including inhalation and long-acting injectables as well as Biosimilars.”

According to James He, Founder and CEO for ForDoz Pharma Corp, “ForDoz Pharma is excited to partner our complex injectable flagship products with Lupin. Lupin’s leadership presence in U.S. will complement ForDoz’s scientific and complex injectable manufacturing capability to bring affordable medicines to patients in an efficient manner”.

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centres, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Page 1 of 2

Press Release

==> picture [67 x 70] intentionally omitted <==

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN

Please visit www.lupin.com for more information. Follow us on Twitter: www.twitter.com/LupinGlobal | LinkedIn: www.linkedin.com/company/lupin/ Facebook: www.facebook.com/LupinWorld/

About ForDoz

ForDoz Pharma Corporation is a privately-owned specialty pharmaceutical company focusing on development, manufacturing, and commercialization of value-added sterile and complex injectable products such as liposomes, microspheres, micelles, nanosuspensions, and microcrystal-suspensions.

ForDoz Pharma is located in the 27-acre campus at greater Princeton area of New Jersey, a prominent pharmaceutical hub in the United States. At this 27-acre campus, ForDoz has R&D labs, cGMP QC and microbiology labs and a fully qualified and validated sterile complex injectable product manufacturing facility which complies with both US and EU cGMP standards.

ForDoz Pharma is accelerating and improving traditional drug development processes through proprietary particlebased drug delivery technology platform with particle sizes ranging from 10 nm to several µm. At ForDoz Pharma, we can commercialize products as a CDMO partner via a closed loop system, from R&D, analytical testing, process scale-up to commercial manufacturing all from our one single campus.

Please visit www.fordozpharma.com for more information LinkedIn: www.linkedin.com/company/fordoz-pharma-corp/

For further information or queries please contact:

	Arvind Bothra Head – Investor Relations and Corporate Communications Email:arvindbothra@lupin.com Tel: +91 22 6640 8237	Manjira Sharma General Manager – Corporate Communications Email:manjirasharma@lupin.com Tel: +91 22 6640 2532

Page 2 of 2